New Phase II data presented today at the stars and stripes insulin-dependent diabetes pool 69th Scientific Sessions in New Orleans show that the investigational type 2 insulin-dependent diabetes mellitus care Syncria (albiglutide) significantly reduced blood glucose levels and supposing weight loss across weekly, biweekly and monthly dosing. Reducing blood sugar is a key part of managing type 2 diabetes, a disease that affects over 250 million people worldwide.

More: - Brought to my attention by